394 related articles for article (PubMed ID: 33921181)
21. Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors.
Catalano M; Shabani S; Venturini J; Ottanelli C; Voltolini L; Roviello G
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551630
[TBL] [Abstract][Full Text] [Related]
22. Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.
Yadav R; Hakobyan N; Wang JC
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569880
[TBL] [Abstract][Full Text] [Related]
23. Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer.
Jafari S; Molavi O; Kahroba H; Hejazi MS; Maleki-Dizaji N; Barghi S; Kiaie SH; Jadidi-Niaragh F
Cell Mol Life Sci; 2020 Oct; 77(19):3693-3710. PubMed ID: 32006051
[TBL] [Abstract][Full Text] [Related]
24. B7 score and T cell infiltration stratify immune status in prostate cancer.
Zhou Q; Li K; Lai Y; Yao K; Wang Q; Zhan X; Peng S; Cai W; Yao W; Zang X; Xu K; Huang J; Huang H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34417325
[TBL] [Abstract][Full Text] [Related]
25. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 Inhibitors for the Treatment of Prostate Cancer.
Santoni M; Massari F; Cheng L; Cimadamore A; Scarpelli M; Montironi R; Lopez-Beltran A
Curr Drug Targets; 2020; 21(15):1558-1565. PubMed ID: 32516098
[TBL] [Abstract][Full Text] [Related]
27. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated.
Mortezaee K; Majidpoor J; Najafi S
Life Sci; 2022 Dec; 310():121083. PubMed ID: 36265568
[TBL] [Abstract][Full Text] [Related]
28. Emerging Targets of Immunotherapy in Gynecologic Cancer.
Cheng H; Zong L; Kong Y; Gu Y; Yang J; Xiang Y
Onco Targets Ther; 2020; 13():11869-11882. PubMed ID: 33239889
[TBL] [Abstract][Full Text] [Related]
29. Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma.
Elia AR; Caputo S; Bellone M
Front Immunol; 2018; 9():1786. PubMed ID: 30108594
[TBL] [Abstract][Full Text] [Related]
30. Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy.
Yu L; Sun M; Zhang Q; Zhou Q; Wang Y
Front Immunol; 2022; 13():982026. PubMed ID: 36159789
[TBL] [Abstract][Full Text] [Related]
31. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors.
Melaiu O; Lucarini V; Giovannoni R; Fruci D; Gemignani F
Semin Cancer Biol; 2022 Feb; 79():18-43. PubMed ID: 32659257
[TBL] [Abstract][Full Text] [Related]
32. Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy.
Zahm CD; Johnson LE; McNeel DG
Cancer Immunol Immunother; 2019 Oct; 68(10):1661-1669. PubMed ID: 31606777
[TBL] [Abstract][Full Text] [Related]
33. Expression of B7 family checkpoint proteins in cervical cancer.
Zong L; Gu Y; Zhou Y; Kong Y; Mo S; Yu S; Xiang Y; Chen J
Mod Pathol; 2022 Jun; 35(6):786-793. PubMed ID: 34848831
[TBL] [Abstract][Full Text] [Related]
34. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
35. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer.
Kitsou M; Ayiomamitis GD; Zaravinos A
Int J Oncol; 2020 Jul; 57(1):237-248. PubMed ID: 32468013
[TBL] [Abstract][Full Text] [Related]
36. Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma.
Shen S; Chen L; Liu J; Yang L; Zhang M; Wang L; Zhang R; Uemura Y; Wu Q; Yu X; Liu T
Cancer Biol Med; 2020 Aug; 17(3):555-568. PubMed ID: 32944390
[TBL] [Abstract][Full Text] [Related]
37. [Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer].
Huang L; He J
Zhonghua Nan Ke Xue; 2020 Nov; 26(10):944-948. PubMed ID: 33382229
[TBL] [Abstract][Full Text] [Related]
38. Emerging Immunotargets and Immunotherapies in Prostate Cancer.
Montironi R; Santoni M; Sotte V; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Berardi R; Scarpelli M
Curr Drug Targets; 2016; 17(7):777-82. PubMed ID: 26898309
[TBL] [Abstract][Full Text] [Related]
39. Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review.
Kim TJ; Koo KC
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751945
[TBL] [Abstract][Full Text] [Related]
40. Alternative immune checkpoints in immunoregulatory profile of cancer stem cells.
Mortezaee K; Majidpoor J
Heliyon; 2023 Dec; 9(12):e23171. PubMed ID: 38144305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
